Conference Correspondent

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent — December 4, 2015

Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC

ASCO 2015 - Lung Cancer, ASCO, Biosimilars

Conference Correspondent — May 28, 2015

Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Page 29 of 44

26
27
28
29
30
31
32